1 / 18

PANCREAS INSUFFICIENCY

PANCREAS INSUFFICIENCY. Lipase. Bile acids (Conc. >CMC). Micelles. Fatty acid or monoglyceride. Polar end of bile acid. Hydroxyl groups of bile acids. Bile acid. HUMAN PANCREATIC LIPASE. Interfacial enzyme,active in the lipid-water interface

alaina
Download Presentation

PANCREAS INSUFFICIENCY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PANCREAS INSUFFICIENCY

  2. Lipase Bile acids(Conc. >CMC) Micelles Fatty acid or monoglyceride Polar end of bile acid Hydroxyl groups of bile acids Bile acid

  3. HUMAN PANCREATIC LIPASE Interfacial enzyme,active in the lipid-water interface Dependent on clean interface for lipolysis Colipase binds to lipase in presence of bile salts Lipase is specific for primary esterbond Lipase is rapidly and irreversibly inactivated at pH<4

  4. Chylomicron Formation and Secretion Uptake frommicellar solution FA and MG Mitochondria Esterification Granular-endoplasmicreticulum Surfacestabilization Chylomicronformation Addition oflipoprotein Nucleus Secretion viaintercellular spacesinto lacteals Golgi material

  5. Pancreatic Exocrine Function • Normal post-prandial pancreatic secretion is ±70% of maximal secretory capacity or 4–5 times the basal rate • Post-prandial secretion lasts for about 4 hours • Total intraduodenal lipase output varies from300,000 to 500,000 U/meal • Minimum pancreatic function of 10% of normal is necessary for adequate lipid digestion, correspondingto ± 30,000–50,000 U lipase in the duodenum • Amount of lipase, to be added to meals, varies depending upon degree in insufficiency and degree of gastric/duodenal denaturation

  6. Pancreatic Exocrine Insufficiency • Steatorrhea (mild:7–10 g/d; moderate: 10–20 g/d; severe: >20 g/d) • Bile salt precipitation due to low duodenal pH (bicarbonate deficiency)→increased fecal bile salt loss • Impaired CCK and GIP release→sluggishgallbladder emptying • Malabsorption of lipid-soluble vitamins,cholesterol

  7. SYMPTOMATOLOGY OF EXOCRINE PANCREATIC INSUFFICIENCY Steatorrhea and creatorrhea causes -Abdominal complaints -bloating,pain,cramps -urgency,diarrhea,foul smelling stools -Generalised symptoms -weight loss -fatigue,loss of energy -sympoms related to vitamin deficiencies

  8. Exocrine Pancreatic Insufficiency Diagnosis • Suspicion because of associated medical condition and: • clinical history of steatorrhea • weight loss • Laboratory tests • fat balance test (not specific) • non-invasive pancreatic function test • fecal elastase, fecal chymotrypsin, PABA test • invasive direct pancreatic function test (gold standard) • secretin test

  9. Indications for Pancreatic Enzyme Therapy • Exocrine pancreatic insufficiency causing • any moderate / severe steatorrhea • any steatorrhea with weight loss • chronic / watery diarrhea • dyspeptic symptoms • Unrelenting pain in chronic pancreatitis(inhibition of pancreatic secretory drive by negative feedback) (non-enteric coated preparations)

  10. Pancreatic Enzyme PreparationsNon-Enteric Coated Preparations Pancreatin powder / granulate • blends well with food • unpalatable • denaturation in acid / peptic milieu • hyperuricosuria Pancreatin tablet / capsule • inadequate dispersion into the meal • neutral taste • denaturation in acid / peptic milieu

  11. Pancreatic Enzyme PreparationsEnteric Coated Preparations Enteric-coated tablet / capsule (dissolving at pH >5) • prolonged gastric retention causing de-synchronisation • failed or delayed dissolution when duodenal pH is low (lack of bicarbonate) Enteric-coated microspheres (dissolving at pH >5) • premature gastric dissolution when pH >5 during early phase of meal • delayed gastric emptying of particles >1.4 mm • failed or delayed dissolution when duodenal pH is low

  12. Enteric Coated Mini-Doses Preparation Galenic aspects gelatin capsule pH dependent enteric coated layer pancreatin

  13. Microsphere Pancreatic Enzyme Preparations Lipase Amylase Protease sphere diam. • microspheres larger than 1.4 mm empty more slowly than solid phase of the meal • release of enzymes from microspheres is slow, depending upon pH and ionic strength of medium Creon 8,000 9,000 450 1.4 (1.2–1.7) Pancrease 5,000 2,900 330 2.0 (1.7–2.2) Panzytrat 25,000 22,500 1,250 2.0 Creon forte 25,000 18,000 1,000 1.4 (1.2–1.8)

  14. Pancreatic Enzyme PreparationsCourse of dissolution of enteric oat

  15. Pancreatic Enzyme PreparationsDosage recommendations • Enzyme supplementation during all meals • Main meal: 25.000 to 75.000 FIP units lipase of EC preparation • In-between snacks: 5.000 to 25.000 FIP lipase of EC preparation • Dosage should be adjusted for individual patient • Addition of H2-receptor blocker or protonpump inhibitor

  16. Pancreatic Exocrine InsufficiencyDietary recommendations • Abstinence from alcohol • In principle NO limitation of fat content of food (<60 g/d) (unpalatable; risk of deficit of essential fatty acids e.g. linoleic acid) except therapy failure • Frequent small meals • Reduction in fiber content (fiber inhibitspancreatic enzymes) • Medium chain triglycerides (C6-C12)(80–120 g/d) in case of insufficiently corrected steatorrhea and weight loss

  17. Therapy of Pancreatic InsufficiencyTreatment failure • Acid related • inactivation of lipase • precipitation of bile salts • enteric coat dissolves too distally • Related to the use of medication • too low dose • noncompliance • incorrect timing or mode of ingestion • False diagnosis or concomitant disease • celiac disease • bacterial overgrowth

More Related